ClinicalTrials.gg
CompletedNCT06545097ALLEVIATE1Updated Jan 22, 2026

A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty

A Phase 3 interventional study of Cebranopadol 400 ug and Cebranopadol 200 ug in Acute Pain, sponsored by Tris Pharma, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Tris Pharma, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 351 studies in Acute Pain with a site in United States — 47 open to participants now, 53 under way, 1 of them phase 3. Acute Pain · United States.

Enrollment
52nd of 320
279 · median 84
Started
2024
with 26 others
Phase 3
42 of 351
1 open now
Registered
316th of 351
by date

Among the 351 studies in Acute Pain with a site in United States, this one is the 52nd largest by enrollment of the 320 interventional ones that give a count, is one of 27 that started in 2024, is one of 42 in phase 3, and was the 316th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

47 of the 351 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a Abdominoplasty.

Read the detailed description

This study is a Phase 3, multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain after Full Abdominoplasty. This study will be conducted in 3 phases: Screening, Treatment, and Follow-up.

03

Conditions studied

  • Acute Pain

Browse trials for

Keywords

  • Abdominoplasty
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Scheduled to undergo full abdominoplasty procedure without liposuction or other collateral procedures, using anesthesiologic and surgical procedures planned as described in this protocol.
  • Must be able to adhere to the visit schedule, complete all study assessments, and protocol requirements including self-reported questionnaires.

Key Exclusion Criteria:

  • Any disease, medical condition or laboratory finding that in the investigator's opinion may interfere with the study procedures or data integrity or compromise the safety of the subject.
  • Subject has a current painful condition that could confound the interpretation of efficacy, safety or tolerability data in the study, in the opinion of the investigator.
  • History of allergy, or intolerance to any opioid analgesics or anesthetics, including opioid-induced nausea or vomiting.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    Treatment A

    Cebranopadol 400 ug (once daily for 2 days)

    Drug: Cebranopadol 400 ug

  • Experimental
    Treatment B

    Cebranopadol 400 ug on Day 1; 200 ug on Day 2

    Drug: Cebranopadol 400 ug · Drug: Cebranopadol 200 ug

  • Placebo comparator
    Treatment C

    Placebo (once daily for 2 days)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measure

    Pain Numerical Rate Scale (NRS) area under the curve from 4 through 48 hours (AUC4-48)

    Time frame: 4-48 hours

Secondary outcomes

  1. Secondary Outcome Measure:

    Pain Numerical Rate Scale (NRS) AUC4-24

    Time frame: 4-48 hours

  2. Secondary Outcome Measure:

    Number of doses of rescue medication

    Time frame: 48 hours

  3. Secondary Outcome Measure:

    Pain NRS AUC

    Time frame: 24-48 hours

  4. Other Secondary Endpoint

    Pain NRS

    Time frame: Partial AUCs: 4-12, 12-24, 24-36, 36-48, and 4-36 hours

  5. Other Secondary Endpoint

    Rescue Medication

    Time frame: Proportion of subjects who take at least 1 dose of rescue medication up to hours 12, 24, and 36

  6. Other Secondary Endpoint

    MOAA/S

    Time frame: peak sedation, total score and AUC4-48

07

Study locations

4 sites
  • ALLEVIATE 1 Site 001106
    Little Rock, Arkansas 72211, United States
  • ALLEVIATE 1 Site 001112
    Miami, Florida 33014, United States
  • ALLEVIATE 1 Site 001110
    Bellaire, Texas 77401, United States
  • ALLEVIATE 1 Site 001111
    San Antonio, Texas 78240, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Dec 2024, 3 months.

Of 29 industry-sponsored phase 3 interventional studies under Acute Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 54 studies reached it within 14 months; a quarter within 7 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2024
First posted
Aug 9, 2024
StartActual
Sep 3, 2024
Primary completionActual
Dec 30, 2024
CompletionActual
Dec 30, 2024
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06545097
Lead sponsor
Tris Pharma, Inc.
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Sep 3, 2024
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024
Last update
Jan 22, 2026

Study contacts

Harold S. Minkowitz, MD
principal investigator · HD Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion